SANTA CLARA, Calif.—AffymetrixInc. announced recently that Empire Genomics LLC has obtained a non-exclusive,worldwide license to a number of Affymetrix patents covering the manufacturing,use and sales of nucleic acid microarrays and related products and services forcomparative genomic hybridization (CGH). The arrays and services may be usedfor research or diagnostic purposes. Financial details of the license were notdisclosed.
"This agreement with Affymetrix enables Empire Genomics tobring its innovative genomics platform to market while continuing theadvancement of personalized medicine," says Anthony Johnson, president and CEOof Empire Genomics. "We fully expect that focusing in the field of copy numbervariation will lead to the discovery of the genomic causes of multiplediseases, as well as advanced therapeutic treatment strategies."